sorafenib has been researched along with entecavir in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (entecavir) | Trials (entecavir) | Recent Studies (post-2010) (entecavir) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,860 | 248 | 1,424 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, W; Gu, X; Guan, M; Huang, X; Li, X; Qiu, J; Zhang, Y; Zhao, Y; Zhou, Q; Zou, Y | 1 |
| D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P | 1 |
| Hu, YQ; Meyer, S; Moyo, H; Tomlinson, C; Waterhouse, C | 1 |
1 review(s) available for sorafenib and entecavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for sorafenib and entecavir
| Article | Year |
|---|---|
Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Viral; Hepatitis B virus; Humans; Liver Neoplasms; Quinazolinones; Virus Replication | 2020 |
Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma?
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome | 2013 |
How patent law reform can improve affordability and accessibility of medicines in South Africa: Four medicine case studies.
Topics: Antineoplastic Agents; Antiviral Agents; Costs and Cost Analysis; Drug Costs; Drug Industry; Erlotinib Hydrochloride; Guanine; Health Services Accessibility; Humans; Immunologic Factors; Lenalidomide; Patents as Topic; Pharmaceutical Preparations; Sorafenib; South Africa | 2019 |